Fifteen patients with clinical diagnosis of dilated cardiomyopathy (DCMP) were followed for 3 to 34 months. Serum neopterin and ~rmicroglobulin concentrations were measured by radioimmunoassay. According to the changes of neopterin and ~Tmicroglobulin levels in the follow-up study patients were divided into three groups. The course of disease in group 1 (5 patients with constant normal neopterin level « 9 nmol /L) during the study) was stable without deterioration and increase of New York Heart Association (NYHA) Class. In group 2 (2 patients with raised neopterin in levels at the beginning of the study) some clinical improvement was associated with normalization of neopterin concentration. In group 3 (8 patients) the relation between the disease progression and increasing neopterin level was observed. The data of this study clearly indicated that neopterin measurements had a predictive value in patients with clinical diagnosis of DCMP.
Introduction
Dilated cardiomyopathy is a heart muscle disease of unknown origin which is usually characterized by progressive heart failure with poor prognosis and fetal complications (1 -3) . The possible role of myocarditis in the pathogenesis of DCMP has been investigated extensively in the past several years (3 -6) . It was proved that the development of the pathological process in DCMP is accompanied with pronounced disturbances of immunity (7 -9) . There were observed in some patients with DCMP laboratory features of activation of the immune system such as increased DR antigens, expression of interleukin -. 2 receptors on peripheral blood lymphocytes and raised serum neopterin, l3rmicroglobulin levels (10-13). Numerous clinical studies have shown that different signs of immune activation especially increased neopterin concentration are associated with poor prognosis in patients with cancer, acute allograft rejection and AIDS (14, 15) .
Neopterin, 6-D-erythro-trihydroxypropylpterin, is a low molecular weight compound derived biosynthetically from guanosinetriphosphate (14, 15 (16, 17) . The results of our previous investigations indicated that in DCMP patients raised neopterin level associated with morphological evidence of myocardial inflammation discovered by endomyocardial biopsy (12. 13).
The purpose of this study was to investigate the possible prognostic significance of serum neopterin and ~rmicroglobulin levels in DCMP patients.
Material and Methods
During the previous 2 years 15 patients (14 males and one female , mean age 35 ± 3 years) with clinical diagnosis ofDCMP were studied. Dilated cardiomyopathy was defined according to the WHO criteria (2). In 10 patients cardiac catheterization, coronary arteriography and right and/or left ventriculars endomyocardial biopsies were performed. In 2 patients diagnosis was confirmed at necropsy. 9 cases had a histologic evidence of myocardial inflammation. Symptomatic assessment was made by the New York Heart Association (NYHA) classification: 7 patients were in NYHA C lasses 1 -11 a nd 8 in Classes 111-1Y.
Serum samples from patients were assayed for neopterin and ~z-microglobulin by radioimmunoassay (Henning Berlin, Germany and USS R , respectively) . As described in detail in a previous publication upper normal limits of serum neopterin level were 9 nmol/ L and ~rmicroglobulin -2.4 mg/ L (12). Neopterin and ~r microglobulin concentrations were measured simultaneously in serum of each patient at the time of initial presentation and at various intervals at follow-up visit s (3 , 6, 12, 18, 25 month). All patients got conventional therapy including diuretics, glycosides and vasodi lators. Only one patient with clinical and laboratory signs of bacterial infections had specific therapy including antibiotics, intravenous immunoglobulin and plasmapheresis (see results).
Results
We divided patients into three groups (Table 1 and Fig. 1 ) on the basis of changes in the concentration of neopterin in the follow-up study. Two patients with high neopterin levels (28 a nd 14 nmol/ L) were included in group 2. The first patient with natural history of DCMP for about a year had an episode of acute bacterial infection at the beginning of our study. His condition improved after specific therapy and signs of acute inflammatory process disappeared . Another patient had morphologic evidence of myocardial inflammation. In these two patients clinical improvement was associated with decreasing serum neopterin levels. In group 3 -(8 patients) the disease progression was associated with increasing serum neopterin level during the follow-up study. The established signs of high risk mortality (11 -1 Y NYHA classes, serious ventricular arrhythmias, pulmonary or systemic embolism, low ejection fraction (18, 19) were found in patients with the highest neopterin level in continuation of the investigation. Five patients from this group died during the follow-up study.
Discussion and Conclusion
The data of this stud y clea rly indicated that neopterin measurements had a predictive value in patients with clinical diagnosis of D C MP. Similar results were observed in HTV -1 sero positives (20) . Higher neopterin concentrations were significantly associated with more rapid development of AIDS and with earlier AIDS-associated death in clients (20, 21) . Several clinical studies have proved that neopterin represen ts an early, specific and sensitive marker for in vivo T cell activation (14, 15) . Therefore the raised serum neopterin levels in some patients with clinical diagnosis of DCMP suggest that the observed rapid progression in this group could be associated with a high degree of activation of cellular immunity.
Other marker of the immune system activation is ~2-microglobulin (23, 24) . The correlation between the serum neopterin and ~2-microglobulin concentrations in DCMP was established in our previous studies (12, 13) . Similar changes in neopterin and ~z-microglob ulin levels during the follow-up study were revealed. But neopterin seems to be a more specific and sensitive marker of the immune system activation compared with ~rmicroglobulin (25).
Our results allow us to suggest that changes of serum neopterin concentration may predict the outcome in DCMP patients.
